the growth factors ( gf ), which can be employed with this invention , are members of the group of epidermal growth factors ( egf ) or of insulin - like growth factors ( igf ) or of transforming growth factors beta ( tgf - beta ) or of the fibriloplast growth factors ( fgf ). it is also possible to employ suitable combinations of two or more of these growth factors . many of the above growth factors are commercially available as freeze - dried powders which are converted into one of the following formulations for producing implants in accordance with this invention : a ) into a solution with a suitable solvent , for example water or 0 . 1m acetic acid for igf , wherein concentrations of 1 to 10 ng / ml are advantageous ; c ) encapsulated or deposited in biodegradable material , wherein the encapsulation of the gf in micro - capsules made of a suitable biodegradable material , such as polylactide , can be performed for example by means of “ in water drying ” of w / o / w emulsions . massive microspheres can be produced from a gf - polymer - solvent mixture , for example by means of “ spray - drying ”. if the gf is to be introduced into large polymer bodies , this can be done by admixing the gf to the polymer material prior to or during the extrusion process while producing bars or tape - shaped extrudates at low temperatures , or later on by means of an infusion technique such as described by h . zia et al . in “ encapsulation and controlled release ”, thomas graham house , cambridge , pages 117 to 130 ( 1996 ); all of the above mentioned formulations are well documented and can be found in textbooks , such as , for example : d . r . karsa and r . a . stephenson , “ chemical aspects of drug delivery systems ”, thomas graham house , cambridge ( 1996 ); or d . r . karsa and r . a . stephenson , “ encapsulation and controlled release ”, thomas graham house ; or the journal of controlled release of elsevier science ; or the product information of various suppliers , for example sigma - aldrich ® or promega ™. the heat stability of all possible growth factors , except for egf , is very limited , both in solution or freeze - dried . in accordance with the conventional state of the art , process temperatures above 100 ° are required , for example in connection with an injection molding process , in order to obtain implants with the desired mechanical properties . a direct admixture of the growth factors to the polymers prior to or during the production of the implant therefore is not useful . various methods have been developed for being able to charge the finished implants with gfs formulated in accordance with the above described methods : a ) covalent binding of the gfs to the surfaces of the polymer material of the implant . to optimize the deposition process , the surfaces can be pre - treated , for example by means of “ plasma treatment ”, such as described by h . thissen et al . in 1996 during the international symposium on “ biodegradable materials ” in hamburg ; b ) application of a gf - containing film layer of polymer material . this can take place either by dipping the implant into a polymer - gf solution , or by coating with or enveloping the implant in a pre - produced polymer - gf film ; c ) placement in hollow spaces or recesses of the implant is primarily suitable for microscopic or macroscopic polymer - gf mixtures or gf gels . for example , once screwed into the bone , the internal diameter of a hollow screw can be filled with an interlocking polymer - gf rod ; and the implants produced in this manner can have all embodiment shapes customary for osteosynthesis implants . advantageous shapes are plates , bandages , fabrics or other flat or rod - shaped elements . furthermore , connecting elements in the shape of screws , rivets , pins , nails , spiking wires or hoops are produced in accordance with the above described methods . in addition to the growth factors placed into or on the implant , growth factors which are directly introduced into the fracture area can work together with the implant . to this end , the growth factors present in one of the above formulations a ) to f ) are brought into an injectable form and are directly injected into the area of the fracture or its immediate vicinity . in a further advantageous embodiment of this invention , the biodegradable implant can be present spatially separated from the growth factors . in this case the implant is free of growth factors and the growth factors are exclusively present in the injectable formulation . the growth factors which are injected directly into the area of the break or its immediate vicinity act together in an analogous manner with the above described biodegradable osteosynthesis implants , which are free of growth factors . the healing process of a fracture when using an implant in accordance with this invention and the associated growth factors are shown in fig2 a . the solid line shows the accelerated chronological course of the formation of new bone , or respectively the increase of the mechanical load - bearing capacity of the healing bone . the slower increase without the employment of growth factors is represented by the dashed line . although at the time equal to zero the implant must still take on the full mechanical load , it can be made of materials which can be decomposed more rapidly , since it has to bear this load for a much shorter period of time . the conversion of amorphous polymer material into crystallites is also reduced by the shortened presence of the implant in the body , which in turn leads to improved tissue compatibility . the employment of an implant in accordance with this invention with growth factors and additional external stabilization of the break is shown in fig2 b . one advantage of this invention is shown in fig2 b . in addition to the advantages described in connection with fig2 a , the accelerated bone healing here results in a considerable reduction δt of the time the external stabilization means must be worn . the earlier healing of the break and the earlier resumption of the movement of the affected area not only quite decisively reduce the period of sickness , but also quite considerably reduce the outlay in time and money necessary for follow - up treatments . it is apparent to one skilled in the art that the teaching of this invention is not only applicable to human medicine , but that analogously this invention can also be employed by veterinary medicine in connection with all vertebrates . ideally , the growth factors of the respective types or species of animals are used in this case .
an osteosynthetic implant for a mechanical connection of fractured elements , made of a polymeric biodegradable base material , for use in reconstructive osteosynthesis . an active ingredient assists the regeneration of bone tissue in a fracture area and acts together with the implant to assist growth in the fracture area , so that the mechanical load - bearing capability of the healing fracture increases faster or at least as fast as the load - bearing capability biodegradable implant decreases when decomposing .